Australia's full-line pharmaceutical wholesalers say the power failure to the entire state of South Australia is a telling reminder of the benefits of National Medicines Policy and value of the CSO.

Bayer has welcomed a decision by the Complaints Resolution Panel in relation to a claim made by Johnson & Johnson in advertising materials for hayfever allergy product ZYRTEC.

The review of the R&D Tax Incentive has found the program falls short of meeting its stated objective of additionality and spillovers, recommending a series of changes including the introduction of a premium designed to address Australia's poor record on collaboration.

Health Minister Sussan Ley has made it very clear she will not accept "aggressive approaches" from stakeholders.

Approval times for new chemical entities and generics improved last year according to the TGA performance report for 2015-16.

Medicines Australia and other business groups have welcomed publication of the review of the R&D Tax Incentive.

People might not think yesterday's announcement on changes to tax arrangements for working holiday makers has any relevance for the pharmaceutical or wider health sector - take another look.

Shock horror - medical education sponsored by pharmaceutical companies influences prescribing! Isn't that the point?

Industry has made so little use of independent reviews the Department of Health has downgraded its administrative support for the process by scrapping the role of standing convenor.

For Pfizer's Melissa McGregor, her recent appointment as country manager of Pfizer Australia was the next step in a deeply personal journey that started in the Victorian country town of Mildura.

The original listing of GLIVEC in 2002 was a significant moment in the PBS given the speed at which it navigated the reimbursement process - five days.